Interview With Janssen Doctor Explores Potential Bladder Cancer

Every year, roughly 80,000 Americans receive a bladder cancer diagnosis. Many endure difficult and burdensome treatments in an attempt to fight the disease. But new innovations just might change that.

Landmarks in non-muscle-invasive bladder cancer

Role of biomarkers, targeted therapy and tumour mutations in the landscape of bladder cancer - ecancer

Paige and Janssen Deploy AI Based Biomarker Test For Bladder Cancer

The Fascinating Story Behind a New Bladder Cancer Treatment

Johnson & Johnson Innovative Medicine on LinkedIn: In Conversation With Sylvie Laquerre, Ph.D., Janssen Oncology

Advances in immunotherapies and targeted treatments for patients

An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer

/wp-content/uploads/2023/06/

KIF4A promotes tumor progression of bladder cancer via CXCL5 dependent myeloid-derived suppressor cells recruitment

/wp-content/uploads/2023/06/

Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial)

General Healthcare - European Medical Journal

Urine-derived bladder cancer organoids (urinoids) as a tool for cancer longitudinal response monitoring and therapy adaptation

Janssen's global head of R&D opens up on CAR-T research, data science and more - Drug Discovery and Development

Bladder cancer Nature Reviews Disease Primers